Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 0.72 |
| ▸ | EDNRB | P24530 | 12/20 | 0.72 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | DHPS | P49366 | 1/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.59 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7993702 | 0.90 | EDNRA (0.70) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7996794 | 0.88 | EDNRA (0.80) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7990436 | 0.86 | EDNRA (0.61) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7993837 | 0.86 | EDNRA (0.60) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7979121 | 0.84 | EDNRA (0.68) | EDNRAEDNRB | |
| SCHEMBL7978930 | 0.84 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7994045 | 0.84 | EDNRA (0.73) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7448560 | 0.83 | EDNRA (0.60) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7993553 | 0.81 | DHPS (0.50) | EDNRAEDNRBDHPS | |
| SCHEMBL7993453 | 0.81 | EDNRA (0.55) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001081338-A1 | SUBSTITUTED SULFONYLAMINOPYRIMIDINES | ACTELION PHARMACEUTICALS LTD (CH) | 2001-11-01 | — | — | WO | disclosed |